Alexandra LEARY
GINECO - Gustave Roussy · Gustave Roussy, Cancer Campus, Grand Paris · Gustave Roussy center, Villejuif, France
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alexandra LEARY as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:33 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04713514 · OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OCARCAGY/ GINECO GROUP · active not recruiting · Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer · principal investigator
- Ph1/Ph2NCT03249142 · Immunotherapy With Neo-adjuvant Chemotherapy for OVarian CancerARCAGY/ GINECO GROUP · completed · Ovarian Cancer · principal investigator
- Ph1NCT02978755 · First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological CancersGamaMabs Pharma · completed · Neoplasm, Gynecologic · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:33 UTC. The ranking covers the 200 most relevant of 68 PubMed records, and a shared surname and initials can bring in a namesake. All 68 on PubMed
- 2,326 citationsRCR 81.5
- 1,419 citationsRCR 44.3
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.Lancet Oncol · 2017974 citationsRCR 29.9
- Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.J Clin Oncol · 2019885 citationsRCR 34.7
- Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.J Clin Oncol · 2023441 citationsRCR 39.9
- 365 citationsRCR 18.6
- Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.Ann Oncol · 2023333 citationsRCR 29.6
- 329 citationsRCR 17.3
- 233 citationsRCR 7.3
- 221 citationsRCR 27.6